Previous studies on intact cells have shown that bryostatin 1 (Bryo 1) induces significant alterations in the membranes of WSU-CLL cells (a drug-resistant B-CLL cell line), changes which may play an important role in the mechanism of reduced drug resistance of B-CLL cells to 2-chlorodeoxyadenosine (2-CdA). However, it is not clear whether the plasma membranes or the mitochondria, or both are involved; nor is it known which of these two targets is more important for regaining the cells former drug sensitivity. For the present study, we treated WSU-CLL cells with Bryo 1, isolated plasma membranes and mitochondria, and then subjected the purified fractions to infrared (IR) spectroscopic and chromatographic analyses. IR spectroscopy revealed a decreased glycosylation of both plasma membranes and mitochondria in Bryo 1-treated cells compared to untreated cells. The amount of lipid relative to protein was increased in both types of membranes, but considerably more enhanced in the plasma membrane fraction of the Bryo 1-treated cells than in mitochondria. Quantitative lipid analysis by thin layer chromatography also revealed that Bryo 1 treatment significantly increased the phospholipid content in plasma membranes, whereas the lipids in the mitochondria remained essentially unchanged. Changes in lipid composition were quite dramatic for plasma membranes where phosphatidylcholines were decreased by 50%, phosphatidylethanolamines doubled and sphingomyelins increased five-fold compared to the lipid composition in plasma membranes of untreated cells. In addition, the IR spectroscopic analysis provided evidence for an increased plasma membrane fluidity in Bryo 1-treated cells, whereas the fluidity of the mitochondria remained essentially unchanged; marker bands indicating mitochondrial DNA decreased upon Bryo 1 treatment. These results suggest that Bryo 1 increases the sensitivity of WSU-CLL cells to chemotherapeutic agents such as 2-CdA by action on two cell targets: (1) introduction of significant changes in plasma membrane permeability or fluidity through modifications in lipid content and composition as well as by reducing the surface glycosylation; (2) introduction of changes in lipid and DNA content of the mitochondria. Small alterations in the lipid composition of the mitochondria may provide the conditions for an altered proton gradient and transmembrane potential leading to apoptosis and decreased cell survival.
Introduction
Chronic lymphocytic leukemia (CLL) is a malignant disease characterized by the accumulation of morphologically mature, yet immunologically immature B lymphocytes in the peripheral blood, marrow and the lymphoid organs. 1 Although it runs an indolent clinical course, current therapeutic options remain unsatisfactory and a cure has remained elusive. 2 The use of differentiating agents and other biologic response modifiers have brought new and promising treatment strategies. 2, 3 One of these differentiating agents is bryostatin 1 (Bryo 1), a macrocyclic lactone originally isolated and purified from the marine invertebrate Bugula nertina by Pettit et al. 4 Bryo 1 shares similar biological properties with phorbol esters, eg it binds to, activates and translocates protein kinase C (PKC), but unlike phorbol esters Bryo 1 lacks tumor-promoting activity. 5, 6 PKC belongs to an enzyme family of serine/ threonine kinases involved in the transduction of signals for cellular proliferation and differentiation. PKC has been used as a potential target for anticancer therapy since this kinase plays an important role in neoplastic transformation, carcinogenesis and tumor cell invasion. 7 Bryo 1, a partial PKC agonist, has shown potent antineoplastic properties in vitro and in vivo.
Bryo 1 has been reported to have the ability to regulate the growth and differentiation of hematopoietic cells including leukemic cells from patients and leukemia cell lines. [8] [9] [10] Various aspects of cellular changes in CLL cells induced by Bryo 1 treatment include increased RNA synthesis, plasmacytoid morphological changes and immunoglobin production by CLL cells in vitro. 8 Al-Katib et al 10 found that Bryo 1 treatment of CLL cells can upregulate CD22 and CD11c, induce TRAP, and cause further differentiation of CLL cells to the hairy cell stage. Several investigators also reported that Bryo 1 can induce apoptosis, increase DNA fragmentation and augment the inhibitory effects of chemotherapeutic drugs in CLL cells, human myeloid leukemia cells and human diffuse large cell lymphoma. [11] [12] [13] In an earlier infrared (IR) spectroscopic study we found that Bryo 1 can alter the cellular lipid and protein composition in WSU-CLL cells.
14 These changes may play an important role in the drug resistance of this B-CLL cell line to 2-CdA. However, it remained unclear whether changes in the plasma membrane (transport into the cell) or the mitochondrial membrane (energy supply) were responsible for the altered drug sensitivity. In this follow-up study, we therefore treated WSU-CLL cells with Bryo 1, isolated the cell membranes and the mitochondria and then analyzed the purified fractions by IR spectroscopy and thin layer chromatography in order to determine the effects of the Bryo 1-treatment on structure, function and composition of the plasma membranes and the mitochondria.
Materials and methods
Synthetic Bryo 1 was kindly provided by the National Cancer Institute (NSC 339555, IND 42780), Bethesda, MD, USA. It was dissolved in dimethyl-sulfoxide at 10 −3 m, 13 further diluted with PBS and then added directly to the culture medium for the desired final concentrations (100 nm/200 nm). 2-CdA was obtained from Ortho Biotech (Raritan, NJ, USA) as a premixed solution (1 mg/ml). It was also diluted with PBS and then added to the culture medium for a final concentration of 11.2 m. RPMI 1640 was obtained from Gibco Laboratories (Grand Island, NY, USA) and fetal bovine calf serum was purchased from Professional Diagnostics (Edmonton, AB, Canada).
WSU-CLL line
The WSU-CLL line was established at Wayne State University from a 66-year-old male with CLL refractory to CVP (cyclophosphamide, vincristine and prednisone), fludarabine and VAD (vincristine, adriamycin and dexamethasone). 13 These cells grow as a suspension in liquid culture and form subcutaneous tumors in SCID mice. WSU-CLL cells were maintained in RPMI-1640 medium containing 1% glutamine, 10% fetal bovine serum, 100 units/ml penicillin G and 200 g/ml streptomycin at a density of 2 × 10 5 cells/ml. The cells were treated with 100 nm of Bryo 1 and incubated at 95% air/5% CO 2 at 37°C for 72 h. Experiments were repeated three times. The cell viability was assessed on all the experiments with trypan blue exclusion and was greater than 95% throughout these experiments. Plasma membranes and mitochondria from control and Bryo 1-treated WSU-CLL cells were prepared by differential centrifugations. Specifically, WSU-CLL cells (2 × 10 8 /ml) were suspended in a chilled homogenization buffer (0.25 m sucrose/0.5 mm Tris-HCl, pH 7.4/0.75 mm MgCl 2 ) and disrupted with a dounce homogenizer. The nuclei were sedimented (800 g for 10 min at 4°C) and removed. The post-nuclear supernatant was further centrifuged (10 000 g for 10 min at 4°C) and the mitochondrial pellet was resuspended in a 0.1 m sucrose buffer, overlaid with a 0.3 m sucrose solution and centrifuged at 800 g for 10 min at 4°C. The mitochondrial fraction was further washed with 0.9% NaCl and identified positive on cytochrome c oxidase subunit II (Molecular Probe, Eugene, OR, USA) using Western blotting. The plasma membrane was extracted using the postmitochondrial supernatant and ultracentrifugated at 100 000 g for 60 min at 4°C. The pellet was identified as alkaline phosphatase (ALP) positive and used as plasma membrane. The protein concentration was determined by the method of Lowry et al. 15 
Phospholipid extraction and analysis
Phospholipids of the plasma and mitochondrial membranes, from both untreated (control) and Bryo 1-treated WSU-CLL cells, were extracted by the method of Folch et al. 16 The organic phase was dried under nitrogen and resuspended in 100 l of chloroform:methanol (2:1, v/v). A 80 l aliquot of the lipid suspension was then placed on to a thin-layer chromatography (TLC) plate (silica gel plates, type H, Whatman, Clifton, NJ, USA); the phospholipids were separated in two dimensions according to the method of Poorthuis et al. 17 The phospholipid spots on the TLC plates were first visualized by iodine vapor, removed and then placed into scintillation vials for counting.
Infrared spectroscopy
A 5 l sample of the isolated plasma membranes or the mitochondria was deposited on an infrared-transparent barium fluoride window and quickly dried down to a thin circular film 2-3 mm in diameter. The film was kept in a desiccator under mild vacuum for 5 min, then mounted in a special sample holder using a second barium fluoride window to close up the chamber in order to keep the humidity conditions stable. For each sample, three sets of IR spectra were obtained against the background of a blank barium fluoride window. Analyses were performed using a FTS-60 IR spectrometer (BioRad, Cambridge, MA, USA) equipped with a nitrogen cooled mercury cadmium telluride detector. Spectra were recorded at a nominal resolution of 2 cm −1 with an encoding interval of one wavenumber. For each spectrum, 256 interferograms were co-added and apodized with a triangular smoothing function before Fourier transformation. 
Influx studies using

Statistical analysis
The Student's t-test was used for determination of the statistical significance. The level of significance was defined as P Ͻ 0.05.
Results
Spectral characterization of membranes from control WSU-CLL cells
IR spectra of isolated plasma membranes and mitochondria from control WSU-CLL cells are displayed in Figure 1 . The biochemical components of isolated membranes and membrane particles are lipids, membrane proteins and carbohydrates originating from glycolipids and glycoproteins. All of these three components are represented in the IR spectra, as indicated in range L (2800-3050 cm −1 ), range P (1500-1700 cm −1 ) and range C (950-1200 cm −1 ), respectively. Superficially compared, the spectra of plasma membranes and mitochondria appear quite similar. However, upon more detailed examination certain differences can be seen that reflect the well known properties of these cellular structures. Plasma membranes contain more lipid (relative to protein) than mitochondria (see ester lipid C=O band at 1740 cm −1 and lipid acyl chain CH 2 bands at 2850 and 2921 cm −1
) as the inner matrix of the mitochondria which contains many soluble Infrared spectra obtained from isolated plasma membranes and mitochondria of control WSU-CLL cells. Areas marked L, P and C represent lipid, protein and carbohydrate regions, respectively.
proteins and protein complexes is still intact. The membranes of both fractions also differ significantly in their degree of fluidity, indicated by differences in the actual band positions (2850.8 cm −1 for plasma membranes and 2852.3 cm −1 for mitochondria). Although the fluidity of the plasma membranes is lower (lower wavenumber position) than that of the mitochondria, the amount of unsaturated lipids in plasma membrane is approximately twice that in mitochondria (see olefinic = CH band at 3012 cm −1 ) that should cause an increase not a decrease in fluidity. The dissimilar protein composition of the two components is reflected by a different position of the amide I band. The two membranes also differ in their glycosylation as indicated by the different intensity distribution of the carbohydrate bands in the spectral region of 950-1200 cm −1 . Furthermore, the spectrum of the mitochondria indicates the presence of mitochondrial DNA, therefore suggesting that the mitochondria remain intact during isolation (see band at 1713 cm −1 indicating base-paired DNA).
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Bryo 1-induced changes in the membranes of WSU-CLL cells
The changes induced by Bryo 1 in the plasma membrane organization and lipid composition can be observed in the 'difference spectrum' in the top panel of Figure 2 , generated by subtracting the mean spectrum of the control plasma membranes from the mean spectrum of Bryo 1-treated WSU-CLL plasma membranes. These 'difference spectra' help identify specific molecular components that may differ between control and Bryo 1-treated WSU-CLL cells. The negative intensities in the range 950-1200 cm −1 (C for carbohydrate vibrations) and the positive intensities in the range 1500-1700 cm −1 (P for proteins), as well as in the range 1700-1750 cm −1 (L for lipid), indicate that the content of carbohydrates relative to that of protein and lipid is dramatically reduced in Bryo 1-treated cells compared to that in control cells. Furthermore, some typical IR bands of the surface glycosylation in control membranes seem to have disappeared in those of Bryo 1 treated cells (see area marked C, bands at 1026, 1102 and 1157 cm −1 ). Finally, the positive intensity at 1740 cm −1 suggest an increase in the C=O ester components in the plasma membranes following Bryo 1 treatment.
In order to further assess and identify these membrane changes, typical IR marker bands for lipids were evaluated by creating a 'difference spectrum' in the range of 2800-3050 cm −1 ( Figure 3 ). The two methyl bands at 2870 and 2954 cm −1 , which originate from the symmetric and asymmetric stretching vibrations of the acyl chain CH 3 groups, are negative in the IR 'difference spectrum'. In contrast, the two methylene bands at 2851 and 2921 cm −1 , attributed to the symmetric and asymmetric stretching vibrations of the acyl chain CH 2 groups are positive, indicating that Bryo 1 treatment increases the lipid content in the plasma membranes. By plotting the ratio of integrated area (2851/2870 cm −1 ), one is able to obtain information regarding the relative lipid/protein ratio. As shown in Figure 3a , the lipid to protein ratio of Bryo 1-treated membranes increases, indicating an increased lipid content in the Bryo 1-treated cell membranes. The ratio of the integrated area 3012/2851 cm −1 can be used as an index of the relative concentration of double bonds in the lipid structures originating from either unsaturated fatty acyl esters (eg linolenic, arachidonic, etc) or cholesterol. Figure 3b shows that in the Bryo 1-treated membranes the band ratio 3012/2851 cm −1 decreases in comparison to that found in control membranes. Furthermore, the position of the acyl chain methylene bands also changed from 2850 to 2851 cm −1 , indicating a higher degree of fluidity in the membranes of the Bryo 1-treated cells. To corroborate these changes in lipid properties and composition in the plasma membranes of Bryo 1-treated cells, quantitative phospholipid profiles were generated using TLC (see Table 1 ). While apparent from the IR spectra, TLC confirmed that the total phospholipid content of plasma membranes of Bryo 1-treated cells was significantly increased. In addition, also compositional changes of the major phospholipids in the plasma membranes were found. Phosphatidylcholines decreased by 50%, phosphatidylethanolamines doubled in content and the sphingomyelines increased five-fold as compared to the plasma membranes from control cells, an overall change in lipid composition with definite consequences for the cell. Mean IR spectra of plasma membranes from control and Bryo 1-treated WSU-CLL cells (bottom) and difference spectrum generated by subtracting the spectrum of control membranes from that of Bryo 1-treated membranes (top).
Figure 3
Mean IR spectra of plasma membranes from control and Bryo 1-treated WSU-CLL cells in the lipid region and corresponding difference spectrum. (a) and (b) are histograms representing respectively the ratios of the integrated areas (CH 2 /CH 3 ) and (=CH/CH 2 ) in the difference spectrum. Figure 4 shows the two mean spectra of isolated mitochondria from control and Bryo 1-treated WSU-CLL cells, as well as the 'difference spectrum', generated by subtracting the mean spectrum of the control mitochondria from the mean spectrum of Bryo 1-treated mitochondria. The differences in the spectra indicate that Bryo 1 induced similar changes in the mitochondria as those seen in the plasma membranes, ie (1) a decreased amount of carbohydrates, evidenced by the negative difference bands in range C; (2) increased protein and 
Bryo 1-induced changes in the mitochondria of WSU-CLL cells
Figure 4
Mean IR spectra of mitochondria from control and Bryo 1-treated WSU-CLL cells (bottom) and difference spectrum generated by subtracting the spectrum of control membranes from that of Bryo 1-treated membrane (top). lipid content, suggested by the positive intensities in ranges P and L; in addition (3) a decreased DNA content, manifested by the negative difference band at 1713 cm −1 (a marker band for base-paired DNA). The mitochondrial lipid composition was obtained by analyzing the 'difference spectrum' of Bryo 1-treated and control CLL cells in the range of 2800-3050 cm −1 , as shown in Figure 5 . Again, the lipid profiles were altered in a similar way as in the plasma membranes, ie, two negative methyl bands were found at 2870 and 2954 cm −1 , and two positive methylene bands at 2851 and 2921 cm −1 . However, there is no significant change in unsaturated lipids or cholesterol (=CH band) at 3012 cm −1 . Nevertheless, the ratio of the band area for CH 2 /CH 3 groups in Bryo 1-treated mitochondria also increased suggesting a higher lipid content compared to that in control mitochondria ( Figure  5a ). However, the ratio of the band area for =CH/CH 2 groups is almost the same in mitochondria from Bryo 1-treated and control cells (Figure 5b ), suggesting that Bryo 1 does not alter the relative concentration of double bonds in mitochondrial membranes. Furthermore, no significant alterations were observed in the fluidity of mitochondria membranes as the methylene bands do not shift after Bryo 1 treatment.
Quantitative phospholipid profiles of Bryo 1-treated and untreated mitochondria determined by TLC, did not show significant changes in the total phospholipid content or composition ( Table 1) .
Influx of 2-CdA into WSU-CLL cells
To test the altered membrane properties of Bryo 1-treated cells the influx of labeled 2-CdA into B-CLL cells was investigated. The results of these influx studies showed clear evidence for an increased uptake of 2-CdA into the cells after 72 h of Bryo 1 treatment compared to that in control cells. Surprisingly, the analysis of the data indicates no significant difference in the rate constant between the two groups (k mean ± s.d. for Bryo 1 = 0.052 ± 0.023 vs control 0.057 ± 0.025) but a significant difference was found in the V max values (pmol 2-CdA mean ± s.d. for Bryo 1 = 9.84 ± 2.15 vs control = 4.89 ± 1.16; P = 0.007).
Figure 5
Mean IR spectra of mitochondria from control and Bryo 1-treated WSU-CLL cells in the lipid region and corresponding difference spectrum with the ratios of the integrated areas (CH 2 /CH 3 ) and (=CH/CH 2 ) in the difference spectrum (a and b, respectively).
Discussion
Earlier studies have documented that the drug resistance mechanism in different leukemia cells can be studied by IR spectroscopy, for example, the detection of protein changes in doxorubicin-resistant cell lines was associated with changes in the multidrug-resistant (MDR) phenotype related to the membrane transport glycoprotein in resistant cells 19 and it was shown that significant differences exist between the spectra of 2-CdA-resistant and 2-CdA-sensitive CLL cells. 20 More recently, we demonstrated that CLL cells which are sensitive to 2-CdA exhibit similar IR spectral patterns to those of Bryo 1-treated WSU-CLL cells, ie decreased protein and increased lipid content compared to that in control or resistant cells. 14 The present study extends these findings and examines more closely the Bryo 1-induced changes in the composition of plasma membranes and mitochondrial membranes. Bryo 1 induces several important cellular changes in the CLL cell line that result in decreased glycosylation of both the plasma membrane and mitochondria (Figures 2 and 4) while at the same time increasing the relative lipid to protein ratio in both fractions. The fact that the cellular changes induced by Bryo 1 treatment affect mainly lipids was confirmed by the increased phospholipid content and the changed composition of the cell membranes, as assessed by TLC (Table 1) . These results suggest that Bryo 1 may not only enhance the microviscosity of the plasma membrane, but also alter the conformation of membrane proteins such as nucleoside transporters, ion channels, and the MDR receptors. These factors may affect the influx of 2-CdA and possibly that of other chemotherapeutic agents into the interior cellular matrix.
Lipid changes, particularly phospholipid alterations in the cellular membrane, could be a key issue in the Bryo 1-induced differentiation and apoptosis in CLL cells. It is known that a certain phospholipid content in the cell membranes of leukemia cell lines is important for the viability of these CLL cells. For example, a severe loss of viability in human leukemic HL60 cells treated with Ara-C for 24 h was mainly associated with the depletion of phospholipids in their membranes by 20%. 21 In addition, certain phospholipids when expressed in the plasma membrane play an important role in programmed cell death (PCD) or apoptosis. Loss of plasma membrane asymmetry is an early event in apoptotic pathways with the exposure of phosphatidylserines at the outer plasma membrane leaflet. In our model system, the overproduction of lipids into the cell membranes of Bryo-1-treated cells could cause a similar confusion in WSU-CLL cells, although the Bryo 1-induced changes will not cause these cells to die. Several PCD pathways use signal-transduction systems based on membrane receptors and membrane-derived phospholipid precursors as second messengers. 22 Ceramides, for example, derived from the hydrolysis of the plasma membrane phospholipid sphingomyelin, act as a second messenger in activating the apoptotic cascade. The results from this study show that Bryo 1 induces a five-fold increase in the plasma membrane sphingomyelin, which in turn may enhance the diverse cytokine receptors and environmental stresses that utilize ceramide to induce the apoptotic pathway. 23 Furthermore, compositional alterations of phospholipid fractions in human erytholeukemia K562 cells have been shown to be an event during PCD induced with TGF 1 and cis-platin. In this case, PCD was associated with a decrease in phosphatidylethanolamines and an increase in phosphatidylserines, cardiolipines and phosphatidic acids. 24 Since Bryo 1 has been previously shown to induce apoptosis in CLL cells, 13 we suggest that the changes observed in the phospholipid composition of the plasma membrane of Bryo 1-treated CLL cells may be directly related to a specific apoptotic response, which could be an important step in the sensitization of drug-resistant CLL cells to chemotherapeutic agents such as 2-CdA.
The Bryo 1-induced changes in plasma membrane fluidity may directly affect membrane permeability by altering the drug influx/efflux system in the cancerous cells. Dudeja et al. 25 showed that such an alteration in plasma membrane lipid fluidity of KB 8-5-11 resistant cells is one of the important mechanism(s) of MDR reversal by polyoxyethylene surfactants. There is also a favorable correlation between the ability of chemosensitizers to permeabilize lipid bilayers and their capacity to potentiate anticancer drug cytotoxicity. This has been confirmed in lymphoma malignancy variants in that modification of the cell membrane fluidity, either by lecithin or by lecithin-cholesterol mixtures, induced an increase in the uptake of adriamycin in a high proportion of cells of all variants. 26 In doxorubicin-resistant human breast carcinoma MCF-7/DOX cells and murine leukemia P388/DOX tumor cells, the alteration of membrane permeability and fluidity was associated with the MDR down-regulation and an increased drug activity. 27 In the present study, we demonstrated that Bryo 1 treatment rendered WSU-CLL, a drug-resistant cell line, significantly more sensitive to 2-CdA uptake than control cells. These results would suggest that this particular perturbation of the membranes could lower the level of drug resistance in various cancer cells. Whether this observation is a result of only a change in membrane permeability, fluidity, or both, is not known and must await the results from ongoing studies. It also should be seen as a process separate from (or in addition to) changes in membrane receptor or transporter systems.
In addition to the remarkable alterations induced by Bryo 1 in plasma membranes, the lipid to protein ratio in the mitochondria of Bryo 1-treated CLL cells was also increased as seen from the IR spectra, although TLC analysis showed no significant changes in the phospholipid composition compared to that in control cells. There are several possible explanations for this. Firstly, IR spectroscopy may be a more sensitive method than TLC, therefore a minor phospholipid change could possibly be picked up by IR (with proteins as internal standard) but not by TLC. Secondly, the outer mitochondrial membrane is composed of about 50% lipid and 50% protein, while the inner mitochondrial membrane has roughly 80% protein. Therefore, the proportion of lipid to protein in mitochondria is much lower than in plasma membranes as indicated by the IR spectra in Figure 1 . Thus, changes in mitochondrial lipid composition will be less evident than those observed in plasma membranes and could strongly depend on the relative amounts of protein/lipid. The altered lipid content/composition in the Bryo 1-treated WSU-CLL mitochondria may be important for the alterations in drug resistance of CLL cells. Perturbations in the biochemistry of mitochondria have been associated with cell transformation and the acquisition of drug resistance to certain chemotherapeutic agents. 28 Changes in mitochondrial permeability and membrane potential, as well as oxidative stress, are known factors contributing to apoptotic pathways that lead to PCD. Furthermore, mitochondria are one of the targets of anticancer chemotherapy drugs as well as for interferon and reactive oxygen-induced PCD. [29] [30] [31] In this context, a recent study found that drug-resistant leukemic cell lines have increased enzyme activities in their mitochondria and a more active mitochondrial respiratory chain than their parental cell lines. 32 We have demonstrated here that the mitochondria of Bryo 1-treated WSU-CLL cells respond with an increased membrane lipid content, which could easily lead to a reduction of the enzyme activity in the respiratory chain. We also found a significant decrease in mitochondrial DNA (mtDNA). MtDNA, which represents only 0.1-1% of the total DNA in most mammalian cells, is a preferable target for many anticancer drugs vs nuclear DNA because (1) it is not protected by histone or histone proteins, (2) not as well repaired as nuclear DNA, and (3) the negative supercoiled structure makes it more sensitive to any kind of damage. 33 For example, when mtDNA in brain and breast tumor cells is depleted by ethidium bromide treatment, distinct changes were found in the tumorgenic phenotype, loss of the ability to grow in an anchorage-independent fashion and a substantial increase in sensitivity to cytotoxic drugs. 34 These results have also been confirmed in CEM/VLB 100 cells (a human leukemic cell line), where inhibition of mtDNA replication by ethidium bromide has depleted the activity of the mitochondrial electron transport chain, reduced the cellular respiratory rate, and increased the resistance to vinblastine-induced apoptosis. 35 The increased lipid to protein ratio in the mitochondria of Bryo 1-treated CLL cells may therefore not only produce changes in the mitochondrial permeability, respiratory function and enzyme activities, but also be associated with decreased mitochondrial DNA activity.
Finally, our results indicate that Bryo 1 induces a reduction in glycosylation of both plasma membranes and mitochondrial membranes. Glycosylation of membrane proteins (glycoproteins) has been the focus of several drug resistance mechanisms. It has been reported that the pattern of cell glycosylation may reflect the pathological state of the HL60 cells, as glycosylatic patterns of undifferentiated and differentiated HL60 cells exhibit several common glycosidic features that are absent in normal peripheral monocytes. 36 Furthermore, inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype and diminished glucose transporter-1 mediated transport. 37, 38 The decreased glycosylation in the plasma membranes of Bryo 1-treated CLL cells may reflect similar changes in transporters, receptors or ion channels and may be as important as the altered membrane permeability itself for the mechanism involved in increasing the sensitivity to 2-CdA. Given the fact that the protein profile of the plasma membrane proteins shows no significant changes under Bryo 1-treatment, there is a strong possibility for the presentation of new or increased glycolipids in the membrane. Further studies have also to be focused on changes in the variations of glycolipids possibly signaling events such as PCD.
In summary, the present study demonstrates that exposure of WSU-CLL cells to Bryo 1 for 72 h induces overall biochemical changes in both plasma membranes and mitochondrial fractions as determined by IR, TLC and radiolabelling. There are at least two mechanisms by which Bryo 1 is able to enhance the efficacy of 2-CdA in WSU-CLL cells, one that causes changes in the plasma membrane lipid/protein ratio and the phospholipid composition and glycosylation, factors that induce PCD, increase the membrane permeability and fluidity and increase the 2-CdA uptake; a second mechanism induces alterations in the mitochondrial lipid/protein ratio and decreases the mtDNA, factors that may not only affect the respiratory chain, but also the apoptotic pathways.
